<DOC>
	<DOCNO>NCT01813461</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics 14C-labeled isavuconazole route excretion extent metabolism 14C-labeled prodrug BAL8557 .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics 14C-labeled Isavuconazole Following Single Oral Dose 14C-labeled Prodrug Isavuconazonium Sulfate ( BAL8557 ) Healthy Male Subjects</brief_title>
	<detailed_description>Subjects admit stay clinical research unit 23 day . On Day 1 , receive single oral dose BAL8557 throughout study period excretion metabolism study drug monitor .</detailed_description>
	<criteria>The subject body weight least 45 kg body mass index 18 32 kg/m2 , inclusive . The subject 's 12lead electrocardiogram ( ECG ) normal Screening Day 1 ; , abnormal , abnormality clinically significant , include QT interval correct heart rate use Fridericia 's formula ( QTcF ) 430 msec less . The subject 's clinical laboratory test result Screening Day 1 within normal limit clinically significant . Results aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) must within normal range . The subject surgically sterile agrees use highly effective method contraception prevent pregnancy study least 90 day dose Day 1 , subject agree donate sperm least 90 day dose Day 1 . The subject clinically significant disease history condition precludes participate trial . The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT syndrome The subject history bowel obstruction , swallow disorder , severe gastrointestinal disorder , major gastrointestinal surgery , actively bleed hemorrhoid , gastric/duodenal ulcer . The subject irregular bowel habit ( &lt; 1 bowel movement per day ) . The subject nuclear medicine procedure , compute tomography scan , significant xrays ( dental ) within past 12 month , significant occupational radiation exposure , participate radiolabeled study within last 6 month participate one radiolabeled study within last 12 month . The subject positive test hepatitis B surface antigen hepatitis C antibodies Screening know positive human immunodeficiency virus ( HIV ) . The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic admission Day 1 . The subject receive vaccination within last 30 day prior study drug administration . The subject know suspect allergy azole class compound , history multiple and/or severe allergy drug food ( judge Investigator ) , history severe anaphylactic reaction . The subject use tobacco nicotine containing product last 6 month . The subject treatment prescription drug complementary alternative medicine within 14 day prior Day 1 , overthecounter medication within 1 week prior Day 1 , exception occasional use acetaminophen 2 g/day . The subject participate interventional clinical study receive investigational agent within 30 day 5 halflives , whichever longer , prior initiation Screening . The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 . The subject take part strenuous exercise within 3 day prior dose Day 1 . The subject anticipate inability abstain caffeine alcohol use 48 hour prior clinic admission Day 1 throughout duration study ; grapefruit , grapefruit juice , star fruit , Seville oranges product contain item 72 hour prior clinic admission Day 1 throughout duration study . The subject recent history ( within last 2 year ) drug alcohol abuse positive drug screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>BAL8557</keyword>
	<keyword>14C-labeled isavuconazole</keyword>
	<keyword>14C-labeled prodrug isavuconazonium sulfate ( BAL8557 ) / ( [ cyano-14C ] ASP9766 sulfate )</keyword>
</DOC>